Exchange: NASDAQ·Updated 04:10 PM EST
RDHL logo

RDHL RedHill Biopharma Ltd.

$0.261
$0.0423
(13.08%)
Today
Closed $0.281
$0.02
(7.12%)
After Hours
Mkt Cap$2.87M
Vol24,254.00

About RDHL

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a U.S. specialty biopharmaceutical company focused primarily on the development and commercialization of proprietary drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal therapies Rebyota®, for the prevention of recurrent C. diff infection (rCDI), and the bowel preparation treatment, Clenpiq®. RedHill’s key clinical late-stage development programs include: (i) RHB-102 (Bekinda®), with a potential UK MAA for oncology support (chemotherapy and radiotherapy induced nausea and vomiting (CINV/RINV)), positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and is Phase 2-ready for GLP-1/GIP-associated GI intolerance; (ii) opaganib (ABC294640), a first-in-class, orally administered, sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple indications including; prostate cancer, with an ongoing Phase 2 study in combination with darolutamide, neuroblastoma, in collaboration with Penn State University, and for which it has FDA Orphan Drug and Rare Pediatric Disease designations with potential for a Priority Review Voucher (PRV), multiple myeloma with US National Cancer Institute (NCI) grant-funded planned Phase1b/2 clinical studies in partnership with University of Oklahoma, and virus-induced acute respiratory distress syndrome (ARDS); (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a Phase 2-ready study for Crohn’s disease (based on RHB-104's positive U.S. Phase 3 Crohn’s disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and influenza and also targeting multiple cancer and inflammatory gastrointestinal diseases.
50

Neutral Sentiment

How do you feel about RDHL?

WallStWireAds
$RDHL RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth… >> https://caplynx.io/1lgTBKI
focafoca99
$RDHL examined its strategic transformation and expanded commercial growth plan in a virtual investor "What This Means" segment.
DARKP00L
$RDHL 09:18 on Nov. 17 2026 RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor "What This Means" Segment
DARKP00L
$RDHL 09:18 on Nov. 17 2026 RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor "What This Means" Segment
Henry20feb_
$RDHL Hyloris reports that it has more than 30 products and candidates competing for capital and management attention. Management explains that it has begun concentrating resources on programs with clearer prospects for regulatory approval, commercial launches and recurring income. Hyloris is not operating with unlimited resources. more significantly, the company decided in September 2026 to discontinue two other development programs and stop the XTRAZA Phase 3 trial and further U.S. development.

Advertisement|Remove ads.